Cost‐of‐care discussions for individuals with advanced non–small cell lung cancer and melanoma: Findings from a large, population‐based pilot study
Cancer · 2024
DOI: 10.1002/cncr.35380 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2024. Verfasst von K Robin Yabroff und 2 weiteren Autor:innen. Beteiligte Einrichtung: Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Melanoma, Lung Neoplasms, Health Care Costs. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 73 Literaturangaben.
Abstract (Originalsprache)
Background
Costs of cancer care can result in patient financial hardship; many professional organizations recommend provider discussions about treatment costs as part of high‐quality care. In this pilot study, the authors examined patient–provider cost discussions documented in the medical records of individuals who were diagnosed with advanced non–small cell lung cancer (NSCLC) and melanoma—cancers with recently approved, high‐cost treatment options.
Methods
Individuals who were newly diagnosed in 2017–2018 with stage III/IV NSCLC ( n = 1767) and in 2018 with stage III/IV melanoma ( n = 689) from 12 Surveillance, Epidemiology, and End Results regions were randomly selected for the National Cancer Institute Patterns of Care Study. Documentation of cost discussions was abstracted from the medical record. The authors examined patient, treatment, and hospital factors associated with cost discussions in multivariable logistic regression analyses.
Results
Cost discussions were documented in the medical records of 20.3% of patients with NSCLC and in 24.0% of those with melanoma. In adjusted analyses, privately insured (vs. publicly insured) patients were less likely to have documented cost discussions (odds ratio [OR], 0.54; 95% confidence interval [CI], 0.37–0.80). Patients who did not receive systemic therapy or did not receive any cancer‐directed treatment were less likely to have documented cost discussions than those who did receive systemic therapy (OR, 0.39 [95% CI, 0.19–0.81] and 0.46 [95% CI, 0.30–0.70], respectively), as were patients who were treated at hospitals without residency programs (OR, 0.64; 95% CI, 0.42–0.98).
Conclusions
Cost discussions were infrequently documented in the medical records of patients who were diagnosed with advanced NSCLC and melanoma, which may hinder identifying patient needs and tracking outcomes of associated referrals. Efforts to increase cost‐of‐care discussions and relevant referrals, as well as their documentation, are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA.
- Information Management Services, Calverton, Maryland, USA.
- Healthcare Delivery Research Program, National Cancer Institute, Bethesda, Maryland, USA.
ORCID-Profile: K Robin Yabroff, Karen Mittu, Michael T Halpern
Zitieren
APA
Yabroff, K. R., Mittu, K., & Halpern, M. T. (2024). Cost‐of‐care discussions for individuals with advanced non–small cell lung cancer and melanoma: Findings from a large, population‐based pilot study. Cancer. https://doi.org/10.1002/cncr.35380
Vancouver
Yabroff KR, Mittu K, Halpern MT. Cost‐of‐care discussions for individuals with advanced non–small cell lung cancer and melanoma: Findings from a large, population‐based pilot study. Cancer. 2024. doi:10.1002/cncr.35380
BibTeX
@article{Yabroff2024,
author = {Yabroff, K Robin and Mittu, Karen and Halpern, Michael T},
title = {Cost‐of‐care discussions for individuals with advanced non–small cell lung cancer and melanoma: Findings from a large, population‐based pilot study},
journal = {Cancer},
year = {2024},
doi = {10.1002/cncr.35380}
}
EUVIMED